Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.
about
Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer riskSecond solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioningThe Risk of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia in Hodgkin Lymphoma has Substantially Decreased in the ABVD Era Abolishing Mechlorethamine and Procarbazine and Limiting Volumes and Doses of RadiotherapyTherapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology GroupCytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden HospitalRisk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trialsSecond primary malignancies after treatment for malignant lymphoma.Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic miceSecond malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma - characteristics and risk factor analysis.Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.DNA interstrand cross-linking by epichlorohydrin.Quantitative PCR analysis of diepoxybutane and epihalohydrin damage to nuclear versus mitochondrial DNA.Secondary malignancies across the age spectrum.Therapy-related myeloid malignancies in myelomaOptimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience.Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation.
P2860
Q24245375-0742C676-7142-4361-975F-3822880A9B23Q34325244-EEDA3CE5-23F8-4396-9CDD-100DB4B451D4Q34639390-4D12B76E-B9CF-4BD6-9CEE-8D18A9B3CA0AQ35615792-F9284C37-3DCA-47F4-ADCC-32A9B8343E88Q36384679-CADCD2B5-280F-4CC2-8C2A-22F729E36044Q36419982-320C92A5-594B-45DB-83BE-A3BC76DC4BAAQ36589635-8DD061EB-687B-4982-8011-FB449FC80F58Q36615187-ADBA0CBA-BFFB-45A4-8803-4FA3A729D082Q36672691-B5056500-63BC-4653-9EA5-58E8B78B23A8Q36835079-02CE72A9-7873-4E10-AC69-39535DA65DB6Q36936841-263C5CF1-F5AC-4607-8F6D-1461A446EB9EQ37103073-E0D16526-559E-43B4-83FE-7871EC2B7A69Q37307608-5E0A91E6-E934-4C1D-8622-C847B1ECD6B0Q37307722-A9EF88FF-8A54-4168-A668-50FB4942A9E5Q37379773-0FCEC80F-6C81-420E-B59B-43F24EC068C2Q39209765-1970AEB8-F5F2-43B8-B119-B13C7B56EBBAQ40044179-ECBC92C3-798A-49C7-9A15-873CCD744E23Q40239182-4B707D5D-06F5-4AE9-88B9-A3E1653B5595Q44051866-D77BC04C-A369-4C2E-A7C7-EE432DC99636
P2860
Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Leukemia risk following Hodgki ...... erapy, and bone marrow damage.
@en
Leukemia risk following Hodgki ...... erapy, and bone marrow damage.
@nl
type
label
Leukemia risk following Hodgki ...... erapy, and bone marrow damage.
@en
Leukemia risk following Hodgki ...... erapy, and bone marrow damage.
@nl
prefLabel
Leukemia risk following Hodgki ...... erapy, and bone marrow damage.
@en
Leukemia risk following Hodgki ...... erapy, and bone marrow damage.
@nl
P2093
P1476
Leukemia risk following Hodgki ...... erapy, and bone marrow damage.
@en
P2093
A Hagenbeek
A M Chorus
A W van den Belt-Dusebout
E H van Kerkhoff
F E van Leeuwen
H M Pinedo
P304
P356
10.1200/JCO.1994.12.5.1063
P407
P577
1994-05-01T00:00:00Z